Seroxyn(25 mcg+250 mcg)/puff

Seroxyn (25 mcg+250 mcg)/puff is a combination inhaler used for the regular, long-term treatment of asthma in patients who require both a long-acting bronchodilator and an inhaled corticosteroid. It brings together two complementary mechanisms of action in a single device, making maintenance therapy more convenient for patients who would otherwise need two separate inhalers.

This combination is specifically indicated for:

• Asthma patients who are not adequately controlled on inhaled corticosteroids alone, along with an "as needed" short-acting beta-2 agonist
• Asthma patients who are already stable on both an inhaled corticosteroid and a long-acting beta-2 agonist, where a combined device can simplify the treatment regimen
• Chronic Obstructive Pulmonary Disease (COPD) patients with a history of repeated exacerbations, despite regular bronchodilator therapy, who need symptomatic relief and reduced exacerbation frequency

It is important to note that this medicine is intended for the prevention and control of symptoms, not for the relief of a sudden asthma attack. A fast-acting rescue inhaler should always be kept available for acute breathlessness.

Seroxyn (25 mcg+250 mcg)/puff belongs to the therapeutic class of long-acting selective beta-2 adrenoceptor stimulants combined with respiratory (inhaled) corticosteroids. It is classified as a fixed-dose combination bronchodilator and anti-inflammatory respiratory agent.

This combination inhaler works through two distinct but complementary mechanisms that together improve airflow, reduce airway inflammation, and lower the frequency of asthma or COPD exacerbations.

Salmeterol

Salmeterol is a selective, long-acting beta-2 adrenergic agonist with a duration of action of approximately 12 hours. Its unique long side chain allows it to bind to an exo-site on the beta-2 receptor, producing sustained bronchodilation. By relaxing the smooth muscle lining the airways, salmeterol widens the bronchial passages and protects against bronchoconstriction triggered by allergens, exercise, or cold air.

Fluticasone Propionate

Fluticasone Propionate is a synthetic corticosteroid with potent glucocorticoid and negligible mineralocorticoid activity. When inhaled at recommended doses, it acts locally within the lungs to suppress airway inflammation, reduce mucosal swelling, and decrease mucus secretion, all without producing the systemic effects typically seen with oral corticosteroids.

Combined Effect

Used together, salmeterol provides rapid and sustained symptom control while fluticasone propionate addresses the underlying inflammatory process, improves lung function, and reduces the risk of future exacerbations. This dual action makes the combination more effective than either component used alone for long-term airway disease management.

Correct inhaler technique is essential for this medicine to work effectively. Studies show that many patients do not use their inhalers properly, which reduces the amount of medicine reaching the lungs and can lead to poor symptom control. Following the steps below, based on the National Asthma Guidelines for Medical Practitioners, will help ensure maximum benefit from each dose.

• Remove the cap from the mouthpiece.
• Shake the inhaler vigorously at least six times before each use.
• If the inhaler is new or has not been used for a week or more, shake it well and release one test puff into the air.
• Breathe out as fully as comfortably possible, then hold the inhaler upright.
• Place the mouthpiece between the teeth and close the lips around it without biting.
• Begin to breathe in slowly and deeply through the mouth while pressing down firmly on the canister to release one dose.
• Remove the inhaler from the mouth and hold the breath for about 10 seconds, or as long as comfortable.
• If a second puff is prescribed, wait about one minute, shake the inhaler again, and repeat steps 4 to 7.
• Replace the cap after use and rinse the mouth thoroughly with water to reduce the risk of oral thrush and hoarseness.
• Occasionally check technique in front of a mirror. Seeing a mist escape from the top of the inhaler or around the mouth usually means the lips were not sealed properly or inhalation timing was off; repeat the process carefully.

Cleaning the Inhaler

Clean the inhaler device at least once a week. Remove the metal canister and rinse only the plastic actuator and cap in warm water. Never place the metal canister itself in water. Dry the actuator and cap thoroughly before reassembling, then twist the canister back into place and replace the mouthpiece cap.

Because the amount of drug reaching the bloodstream after inhalation is very small, clinically significant interactions with this combination are uncommon. However, certain precautions should be observed:

• Beta-blockers: Both non-selective and selective beta-blockers (such as propranolol or atenolol) can antagonize the bronchodilating effect of salmeterol and should generally be avoided in patients with asthma unless there is a compelling clinical reason for their use.
• Strong CYP3A4 inhibitors: Medicines such as ketoconazole and ritonavir inhibit the enzyme responsible for metabolizing fluticasone propionate. Co-administration can increase systemic exposure to fluticasone, raising the risk of corticosteroid-related side effects, including adrenal suppression. This combination should be used cautiously and only under close medical supervision.
• Other sympathomimetic agents: Concurrent use with other beta-2 agonists or stimulant medicines may increase the risk of cardiovascular side effects such as palpitations or tachycardia.

Patients should inform their doctor about all prescription medicines, over-the-counter drugs, and herbal supplements they are taking before starting this inhaler.

As this preparation contains both salmeterol and fluticasone propionate, patients may experience side effects associated with either component. Combining the two drugs does not appear to increase the overall rate of adverse events compared to using each individually.

Side Effects Related to Salmeterol

• Fine tremor and subjective palpitations, usually transient and reducing with continued therapy
• Headache
• Cardiac arrhythmias, including atrial fibrillation, supraventricular tachycardia, and extrasystoles, mainly in susceptible individuals
• Joint pain (arthralgia)
• Hypersensitivity reactions such as skin rash, swelling, or angioedema
• Throat irritation
• Muscle cramps (rare)

Side Effects Related to Fluticasone Propionate

• Hoarseness of voice
• Oral and throat candidiasis (thrush)
• Skin hypersensitivity reactions
• Facial and throat swelling (rare)

The risk of hoarseness and oral thrush can be significantly reduced by rinsing the mouth with water immediately after each use of the inhaler. Patients who notice persistent white patches in the mouth, voice changes, or unusual heart rhythm symptoms should consult their physician.

Use in Pregnancy

There is limited clinical experience with the use of salmeterol and fluticasone propionate in human pregnancy. This medicine should only be used during pregnancy if the expected benefit to the mother clearly outweighs any potential risk to the developing fetus. Animal reproductive toxicity studies have shown fetal effects consistent with excessive systemic exposure to a potent beta-2 agonist and glucocorticosteroid, though these were observed at doses well above the recommended human inhaled dose.

Use During Breastfeeding

Data on the use of this combination in breastfeeding mothers are limited. Because plasma concentrations of both salmeterol and fluticasone propionate after inhaled therapeutic doses are very low, transfer into breast milk is expected to be minimal, a finding supported by studies in lactating animals. Even so, this inhaler should only be used during breastfeeding if the anticipated benefit to the mother outweighs any possible risk to the infant.

Pregnant or breastfeeding women should always consult their physician before starting or continuing this medication.

Not for Acute Symptom Relief

This inhaler is a maintenance treatment and must not be used to relieve sudden or worsening breathlessness. A fast-acting, short-acting bronchodilator such as salbutamol should always be kept on hand for acute symptoms, and patients should be counselled accordingly.

Do Not Start During an Exacerbation

Treatment should not be initiated in patients experiencing an asthma exacerbation or those with unstable or rapidly deteriorating asthma, as this may require a different, more intensive approach to therapy.

Risk of Worsening Symptoms

Patients should be advised to continue regular treatment but seek prompt medical advice if asthma symptoms remain poorly controlled or worsen after starting this inhaler, since serious asthma-related events can occur.

Paradoxical Bronchospasm

As with other inhaled therapies, this medicine can rarely cause paradoxical bronchospasm, marked by an immediate increase in wheezing after dosing. If this occurs, treatment should be stopped immediately, a fast-acting inhaled bronchodilator administered, and the patient assessed by a doctor before considering alternative therapy.

Pneumonia Risk in COPD

Clinical studies have shown an increased reporting of pneumonia among COPD patients using salmeterol/fluticasone inhalers. Because the symptoms of pneumonia and a COPD exacerbation often overlap, physicians should remain alert for signs of lung infection throughout treatment.

Corticosteroid-Related Systemic Effects

Although fluticasone propionate acts mainly within the lungs, systemic effects can occur with any inhaled corticosteroid, particularly at high doses used over long periods. These effects are much less likely than with oral steroids but may include Cushing's syndrome, Cushingoid features, adrenal suppression, reduced bone mineral density, growth retardation in children, cataracts, glaucoma, and rarely, behavioral changes in children and adolescents. Patients should be reviewed regularly, and the dose should be titrated to the lowest level that maintains effective control.

No specific human data exist for overdose with this combined inhaler, but effects have been documented separately for each component.

Salmeterol Overdose

Signs and symptoms of salmeterol overdose may include seizures, angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitations, nausea, dizziness, fatigue, malaise, and insomnia. Overdose may also cause hypokalemia and hyperglycemia. Management involves discontinuing salmeterol and, where necessary, cautious use of cardioselective beta-blocking agents, with care taken in patients who have a history of bronchospasm.

Fluticasone Propionate Overdose

Acute inhalation of excessive fluticasone propionate doses may cause temporary suppression of adrenal function, which typically resolves on its own within a few days without requiring emergency treatment. Chronic overdose can lead to more persistent adrenal suppression, and monitoring of adrenal reserve may be needed. In cases of fluticasone overdose, therapy with this combination inhaler can generally continue at a suitable dose for ongoing symptom control.

Anyone suspected of significant overdose should seek immediate medical attention.

• Store below 30°C, away from direct sunlight and heat sources.
• This product is supplied in a pressurised canister; do not puncture, break, or incinerate it, even when apparently empty.
• Keep the inhaler away from the eyes.
• Keep out of reach and sight of children.

Children and Adolescents

Orally inhaled corticosteroids, including fluticasone propionate, may cause a reduction in growth velocity when used in paediatric patients. The long-term impact of this effect on final adult height has not been fully established, so growth should be monitored regularly in children receiving prolonged treatment.

Elderly Patients

No dose adjustment is required in elderly patients using the Maxhaler formulation.

Renal Impairment

No dose adjustment is necessary for patients with renal impairment.

Hepatic Impairment

There are no specific data available on the use of this combination in patients with hepatic impairment; caution is advised, and use should be guided by a physician's assessment.